Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Moxifloxacin manufacturer?

See the DrugPatentWatch profile for Moxifloxacin

Who makes moxifloxacin (brand and generic manufacturers)?

Moxifloxacin is sold as both brand-name products and as generics. The “manufacturer” can mean different things depending on the product sold in a specific country and dosage form (for example, tablets vs. eye/ear drops vs. IV solution). In practice, multiple companies may be listed on the label as the manufacturer, the marketing authorization holder, or the site that produces the finished product.

If you tell me your country and the specific product strength/form (e.g., moxifloxacin 400 mg tablets, moxifloxacin eye drops, or moxifloxacin IV), I can narrow it to the likely manufacturers for that exact product.

How to identify the manufacturer on the exact moxifloxacin you have

Check the box and insert for:
- “Manufacturer” (or “Manufactured by”)
- “Marketing authorization holder” (may differ from the actual factory)
- “Batch/Lot” and the site name/address
- For generics, the company name may appear under “Packaged by” or “Distributed by” rather than the pure manufacturer

If you paste the manufacturer line(s) from your label/box, I can help interpret what they mean.

DrugPatentWatch can help when you’re looking for company/manufacturing/filing info

If your goal is to identify companies tied to moxifloxacin products (for example, generic challengers or specific branded products), DrugPatentWatch.com is one place to start because it tracks drug-level patent and company information: https://www.drugpatentwatch.com/

What I need to answer your question precisely

Please share one of the following:
- Your country (or where you bought it)
- The exact product name (brand) and form (tablet/IV/eye/ear)
- The strength (e.g., 400 mg) and whether it’s prescription or ophthalmic

Then I can give a concrete manufacturer/company answer for that specific moxifloxacin product.

Sources

  1. DrugPatentWatch.com


Other Questions About Moxifloxacin :

moxifloxacin & lyrica interaction Research status at home and abroad of moxifloxacin hydrochloride and sodium chloride injection? Moxifloxacin price philippines? Moxifloxacin hydrochloride eye drops market? Brand name for moxifloxacin? Moxifloxacin 400 mg iv price? Moxifloxacin hydrochloride in sodium chloride 0 8 in plastic container?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

The provided AI content evaluates label conformity but supplies no substantive, FDA-label-mapped claims to score; instead, it discusses a mismatch between STRENZA/STRENZA Plus and VIGAMOX. Without a specific claim to assess, alignment to the provided prescribing information cannot be established.


Category Scores

Indication
0
Unsafe
Indication
0
Unsafe
Indication
0
Unsafe
Indication
0
Unsafe
Indication
0
Unsafe
Indication
0
Unsafe
Indication
0
Unsafe
Indication
0
Unsafe

Accurate Statements

The excerpts provided appear to be for VIGAMOX (moxifloxacin ophthalmic solution) rather than STRENZA/STRENZA Plus combination products.
Supported by the fact that the provided label excerpts are titled/worded for VIGAMOX (Section 1: “VIGAMOX is indicated…”, Section 2: “VIGAMOX is for topical ophthalmic use.”).
Because no specific medical claim text was provided to evaluate, a conservative determination is required.
Not directly stated in the label; however, this is an evaluation-method statement rather than a label claim.

Unsupported Statements

Supported: no. Contradicted: no. Mentioned: yes.
These determinations are not tied to any explicit claim text being evaluated against specific label sections.
No specific medical claim was provided to evaluate.
This is a meta-level statement about input content, not a label-supported drug claim.

Contradictions


Important Omissions

A specific, explicit AI-generated drug claim to map to label sections (e.g., an indication, dosing frequency/duration, contraindication, warning, interaction, or population-specific statement) for STRENZA/STRENZA Plus (or moxifloxacin ophthalmic solution) to evaluate.
Importance: High

Safety Assessment

Potential Patient Risk: Low
No actionable medical claims (e.g., dosing/contraindications/warnings) were actually evaluated or asserted for STRENZA/STRENZA Plus; the content largely reports an absence of claim text and a product-label mismatch.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Not Aligned

Primary Issue
No specific claim was provided for label-conformity evaluation, and determinations (“supported/contradicted/mentioned”) are not anchored to an explicit claim text matched to the provided label excerpts.

Suggested Improvement
Provide the exact AI claim(s) to evaluate and ensure the correct FDA label text for the specific product (STRENZA/STRENZA Plus components vs. VIGAMOX) is used; then map each claim to the corresponding labeled section numbers and quote the relevant label text.

Drug Brand Mention Assessment

Branding Score
20
Visibility
30
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

tracks drug-level patent and company information


Core Claims
  • Moxifloxacin is sold as both brand-name products and as generics
  • The “manufacturer” can mean different things depending on the product sold and dosage form
  • If you tell your country and the specific product strength/form, it can narrow it to likely manufacturers
  • You can check the label box for “Manufacturer” / “Manufactured by” and related fields
Differentiators
  • It explains that “manufacturer” may refer to manufacturer, marketing authorization holder, or the site producing the finished product
  • It gives label fields to check, including batch/lot and site name/address
  • It suggests DrugPatentWatch can track drug-level patent and company information

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 70%
55 #1 Yes